HomeDFTX • NASDAQ
add
Definium Therapeutics Inc
Previous close
$17.18
Day range
$16.55 - $17.95
Year range
$14.62 - $18.69
Market cap
1.73B USD
Avg Volume
1.71M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 47.58M | 46.57% |
Net income | -50.44M | -45.18% |
Net profit margin | — | — |
Earnings per share | -0.50 | -21.95% |
EBITDA | -47.45M | -46.16% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 411.59M | 50.36% |
Total assets | 440.10M | 45.66% |
Total liabilities | 107.77M | 77.54% |
Total equity | 332.33M | — |
Shares outstanding | 99.70M | — |
Price to book | 5.11 | — |
Return on assets | -35.14% | — |
Return on capital | -43.69% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -50.44M | -45.18% |
Cash from operations | -42.98M | -69.52% |
Cash from investing | 34.98M | — |
Cash from financing | 245.87M | 6,358.31% |
Net change in cash | 237.88M | 1,204.20% |
Free cash flow | -24.10M | -63.78% |
About
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. Wikipedia
Founded
2010
Website
Employees
105
